Media Pack
News

Current Edition

Volume 16 Issue 2
 
Europe

Study finds lack of racial diversity in cancer drug clinical trials

New research published in JAMA Oncology has found a lack of racial and ethnic diversity in clinical trials for cancer drugs. The study - conducted by researchers fro...
22 August 2019 Europe | news | North America | Regional News
Continue Reading →
news

New drug shows encouraging survival in pancreatic cancer

A clinical trial testing a new drug in pancreatic cancer had promising initial results, report researchers from the University of Michigan Rogel Cancer Center. A ph...
15 August 2019 news | North America | Regional News
Continue Reading →
Europe

AZ, Merck’s latest Lynparza combo win could widen its ovarian cancer reach

The PARP inhibitor Lynparza is in a three-way market battle with GSK's Zejula and Clovis' Rubraca. (AstraZeneca) In the red-hot market for PARP inhibitors, Astra...
15 August 2019 Europe | news | North America | Regional News
Continue Reading →
Europe

Study success strengthens case for Lynparza in ovarian cancer

(Credit: AstraZeneca ) Adding AstraZeneca's Lynparza to Roche's older cancer drug Avastin helped women with advanced ovarian cancer live longer without their tum...
15 August 2019 Europe | news | North America | Regional News
Continue Reading →
Europe

Novartis CEO: ‘We did the best we could’ in Zolgensma data manipulation probe

Zolgensma won FDA approval in May as the drugmaker was working on an internal probe over data manipulation. (Novartis) Amid a fresh scandal, this time over data ...
8 August 2019 Europe | news | North America | Regional News
Continue Reading →
news

FDA ready to crack down as Novartis reveals manipulated Zolgensma data

Novartis' Zolgensma application contained manipulated data, the FDA says. (Novartis) Novartis’ spinal muscular atrophy gene therapy Zolgensma made...
8 August 2019 news | North America | Regional News
Continue Reading →
news

Merck and AZ pile on more positive Lynparza data in bid to break into prostate cancer

Lynparza beat analysts' expectations in the second quarter with $283 million in sales. (AstraZeneca) Two months back, AstraZeneca and Merck made a strong case at...
8 August 2019 news | North America
Continue Reading →
news

Roche trial win for Tecentriq leaves questions unanswered

(Credit: Roche ) Roche on Monday said its immunotherapy Tecentriq helped stave off tumor growth in a Phase 3 study of previously untreated people with metastatic...
8 August 2019 news | North America | Regional News
Continue Reading →
news

Regulators, Gilead at odds over HIV drug’s use in women

(Credit: Wikimedia Commons ) Food and Drug Administration staff appear confident an HIV treatment developed by Gilead can also help prevent the disease from spre...
8 August 2019 news | North America | Regional News
Continue Reading →
news

FDA approves first therapy for rare joint tumor

Today, the U.S. Food and Drug Administration granted approval to Turalio (pexidartinib) capsules for the treatment of adult patients with symptomatic tenosynovial gi...
8 August 2019 news | North America | Regional News
Continue Reading →
 

jcs-white.png

Journal for Clinical Studies

Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.

Facebook Linkedin
Journal For Clinical Studies © 2024, All Rights Reserved – Powered by Teksyte